CRISPR Therapeutics AG (CRSP) Ownership
CRSP ownership summary
as of October 18, 2026- Institutions
- 78.3% of shares outstanding
- Insiders
- 5.90% of shares outstanding
- Shares outstanding
- 96.7M
- Float
- 96.2M shares available to trade
- Short interest
- 22.12% 18.7M shares short
- Days to cover
- 11.76 short interest down 2.1% vs prior month
- Institutions 78.27%
- Insiders 5.90%
- Other investors 15.84%
CRSP top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 9.78% | 9.5M | $466.0M | −1.9M (−16.4%) | June 30, 2026 |
| 2 | BlackRock Inc | 8.63% | 8.3M | $411.2M | +668,904 (+8.7%) | June 30, 2026 |
| 3 | Orbis Allan Gray Ltd | 5.64% | 5.4M | $268.4M | −656,850 (−10.8%) | June 30, 2026 |
| 4 | Capital World Investors | 4.91% | 4.7M | $233.9M | +24,488 (+0.5%) | June 30, 2026 |
| 5 | State Street Corp | 4.47% | 4.3M | $212.8M | +339,166 (+8.5%) | June 30, 2026 |
| 6 | GSK PLC | 3.33% | 3.2M | $158.6M | — | June 30, 2026 |
| 7 | Geode Capital Management, LLC | 2.60% | 2.5M | $123.6M | +132,751 (+5.6%) | June 30, 2026 |
| 8 | T. Rowe Price Investment Management,Inc. | 2.12% | 2.1M | $101.1M | −899,578 (−30.5%) | June 30, 2026 |
| 9 | SR ONE CAPITAL MANAGEMENT, LP | 2.11% | 2.0M | $100.4M | — | June 30, 2026 |
| 10 | Two Sigma Investments LLC | 2.06% | 2.0M | $97.9M | +505,570 (+34.1%) | June 30, 2026 |
| 11 | FMR Inc | 1.97% | 1.9M | $94.0M | −46,191 (−2.4%) | June 30, 2026 |
| 12 | Sumitomo Mitsui Trust Group Inc | 1.78% | 1.7M | $84.7M | −133,141 (−7.2%) | June 30, 2026 |
| 13 | Amova Asset Management Americas, Inc | 1.78% | 1.7M | $84.7M | −133,778 (−7.2%) | June 30, 2026 |
| 14 | EcoR1 Capital, LLC | 1.44% | 1.4M | $68.4M | — | June 30, 2026 |
| 15 | UBS Group AG | 1.36% | 1.3M | $64.9M | −445,031 (−25.2%) | June 30, 2026 |
| 16 | Capital Research & Mgmt Co - Division 3 | 1.31% | 1.3M | $62.5M | +81,613 (+6.9%) | June 30, 2026 |
| 17 | Vanguard Capital Management, LLC | 1.22% | 1.2M | $58.2M | +39,304 (+3.4%) | June 30, 2026 |
| 18 | Bank of America Corp | 1.19% | 1.2M | $56.9M | +172,033 (+17.5%) | June 30, 2026 |
| 19 | NEA Management Company, LLC | 1.09% | 1.1M | $52.1M | — | June 30, 2026 |
| 20 | Charles Schwab Investment Management Inc | 1.09% | 1.1M | $52.1M | +18,488 (+1.8%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 9 holders added 2.0M shares and 7 cut 4.2M.
CRSP top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | ARK Innovation ETF | 6.60% | 6.4M | $314.1M | −498,871 (−7.3%) | September 30, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.83% | 2.7M | $134.7M | −52,050 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 2.41% | 2.3M | $114.5M | −26,816 (−1.1%) | September 30, 2026 |
| 4 | ARK Genomic Revolution ETF | 2.18% | 2.1M | $103.6M | +5,142 (+0.2%) | September 30, 2026 |
| 5 | American Funds New Perspective A | 2.01% | 1.9M | $95.7M | — | September 30, 2026 |
| 6 | American Funds SMALLCAP World A | 1.75% | 1.7M | $83.4M | — | September 30, 2026 |
| 7 | American Funds Growth Fd of Amer A | 1.46% | 1.4M | $69.6M | — | September 30, 2026 |
| 8 | Orbis Global Equity Investor | 1.27% | 1.2M | $60.6M | — | June 30, 2026 |
| 9 | Fidelity Small Cap Index | 1.05% | 1.0M | $50.2M | +8,486 (+0.8%) | July 31, 2026 |
| 10 | Amova ARK Disruptive Innovation A USD | 0.91% | 879K | $43.3M | −63,332 (−6.7%) | August 31, 2026 |
| 11 | T. Rowe Price Mid-Cap Growth | 0.89% | 858K | $42.3M | −191,100 (−18.2%) | September 30, 2026 |
| 12 | Orbis SICAV Global Bal Instl Inv | 0.87% | 838K | $41.3M | +19,622 (+2.4%) | March 31, 2026 |
| 13 | iShares Russell 2000 Value ETF | 0.76% | 731K | $36.0M | +1,108 (+0.2%) | September 30, 2026 |
| 14 | iShares Biotechnology ETF | 0.72% | 700K | $34.5M | −5,304 (−0.8%) | September 30, 2026 |
| 15 | Fidelity Growth Company Fund | 0.61% | 592K | $29.2M | — | August 31, 2026 |
| 16 | Vanguard Russell 2000 ETF | 0.54% | 523K | $25.7M | −13,200 (−2.5%) | September 30, 2026 |
| 17 | Amova ARK Pstv Chg Innovt P JPY Acc | 0.53% | 509K | $25.1M | −24,747 (−4.6%) | August 31, 2026 |
| 18 | Schwab US Small-Cap ETF™ | 0.53% | 509K | $25.1M | +342 (+0.1%) | September 30, 2026 |
| 19 | Fidelity Extended Market Index | 0.49% | 473K | $23.3M | −6,548 (−1.4%) | August 31, 2026 |
| 20 | Orbis Optimal (US$) Fund | 0.40% | 384K | $18.9M | +41,175 (+12.0%) | March 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
CRSP insider transactions
latest 16| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-23 | James R Kasinger | Sell | $46.78 | 3,182 | $148,854 |
| 2026-03-23 | Samarth Kulkarni | Sell | $46.78 | 10,020 | $468,736 |
| 2026-03-16 | James R Kasinger | Sell | $48.26 | 3,450 | $166,497 |
| 2026-03-16 | Naimish Patel | Sell | $48.26 | 3,150 | $152,019 |
| 2026-03-16 | Samarth Kulkarni | Sell | $48.26 | 10,349 | $499,443 |
| 2026-03-11 | James R Kasinger | Sell | $52.80 | 2,800 | $147,840 |
| 2026-03-11 | Samarth Kulkarni | Sell | $52.80 | 9,798 | $517,334 |
| 2026-02-19 | James R Kasinger | Sell | $52.58 | 2,112 | $111,049 |
| 2026-02-19 | Samarth Kulkarni | Sell | $52.58 | 6,967 | $366,325 |
| 2026-01-22 | Samarth Kulkarni | Sell | $60.23 | 60,000 | $3.6M |
| 2026-01-20 | Samarth Kulkarni | Sell | $51.75 | 30,000 | $1.6M |
| 2025-10-17 | Samarth Kulkarni | Sell | $67.91 | 50,895 | $3.5M |
| 2025-10-14 | James R Kasinger | Sell | $66.60 | 1,076 | $71,662 |
| 2025-10-14 | Samarth Kulkarni | Sell | $66.60 | 4,242 | $282,517 |
| 2025-07-16 | Simeon George | Buy | $52.03 | 989,812 | $51.5M |
| 2025-05-29 | Naimish Patel | Sell | $35.94 | 3,932 | $141,316 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
CRSP shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns CRSP
Institutional investors own 78.3% of CRISPR Therapeutics's shares and insiders 5.90%. The largest holder is ARK Investment Management LLC with 9.78% of the shares (9.5M), as of June 30, 2026. Among the top 20 institutions, 9 added shares and 7 reduced their stake in the latest filings. Short interest is 22.12% of the float, or 11.76 days of average trading volume. The share count rose 2,148.1% since 2014.
Related: CRSP analyst forecast, CRSP key metrics. See the CRSP stock overview for the latest quote and news.
CRSP ownership FAQ
Who owns the most CRISPR Therapeutics stock?
The largest shareholders of CRISPR Therapeutics are ARK Investment Management LLC (9.78%), BlackRock Inc (8.63%), Orbis Allan Gray Ltd (5.64%), Capital World Investors (4.91%), State Street Corp (4.47%).
What percentage of CRISPR Therapeutics is owned by institutions?
Institutions hold 78.3% of CRISPR Therapeutics's shares outstanding; insiders hold 5.90%.
Which funds own CRISPR Therapeutics?
The largest fund holders of CRISPR Therapeutics are ARK Innovation ETF (6.60%), State Street® SPDR® S&P® Biotech ETF (2.83%), iShares Russell 2000 ETF (2.41%), ARK Genomic Revolution ETF (2.18%), American Funds New Perspective A (2.01%).
What is CRISPR Therapeutics's short interest?
18.7M shares of CRISPR Therapeutics were sold short, 22.12% of the float; at the average daily volume it would take 11.76 days to cover.
Are insiders buying or selling CRISPR Therapeutics?
Of the latest 16 reported insider transactions in CRISPR Therapeutics (since May 29, 2025), 1 were purchases and 15 were sales.
How many shares of CRISPR Therapeutics are outstanding?
CRISPR Therapeutics has 96.7M shares outstanding, of which 96.2M are in the public float.